AbstractThe single nucleotide polymorphism (SNP) of the promoter region of MMP-1 (at 1607 bp) and MMP-3 (at 1171 bp) create Ets binding sites. Correlations between these SNPs and sensitivity to several biological processes such as metastasis and recurrence of cancer have been reported in several studies.In this case-control study, we looked for these SNPs in women infected with or not with high-risk human papillomaviruses (HR-HPV). The frequency, distribution and correlation of these SNPs with the presence or absence of HR-HPV infection were evaluated.Genotypes 1G1G, 1G2G and 2G2G for MMP1 and genotypes 5A5A, 5A6A, 6A6A for MMP3 were found in our study population. In general, we noted that the 1G (40.8%) and 2G (64.8%) alleles were more frequent in non-infected women and infected women, respectively, and more specifically this difference was significant in women from Côte d‘Ivoire.These results, although yet to be reaffirmed with assays for quantifying the mRNA of these genes, suggest that the SNP of the MMP-1 promoter could promote infection with HR-HPV.

Objectives: A subset of specialized KIR haplotype has been shown to be strongly associated with susceptibility or resistance to viral infections in humans. Therefore, this pilot investigation sought to determine the frequencies of KIR Haplotype in hepatitis B (HBV) and HIV-1 infected patients and their clinical impacts in disease progression and staging in Burkina Faso. Methods: Hepatitis B infected patients, Human Immunodefi ciency virus type 1 (HIV-1) infected individuals and healthy individuals were selected for this study. Hepatitis B surface antigen (HBsAg), anti-HCV antibodies and anti-HIV-1/2 antibody/antigen were screened using a 4 th generation ELISA assay (ARCHITECT I 1000SR ® TM, Abbott Laboratories, USA). In addition, SSP-PCR was used to search the frequencies of KIR haplotype. HBV viral load and HIV-1 viral load was determined in patients along with the CD4+ count. Results: A and B KIR haplotypes was found to be associated with protection against HBV chronic infection evolution to cirrhosis (OR= 0.17, CI95% = 0.03-0.80, P= 0.03) and Hepato-Cellular Carcinoma (HCC) (OR= 0.32, CI95% = 0.11-0.92, P= 0.04). No association was found between markers of HIV infection and KIR haplotypes. No difference was found with regard to the Viral Load of HBV, HIV-1 and KIR haplotype. Conclusion: Our results suggest that A and B KIR haplotypes was associated with protection against HBV chronic infection evolution to cirrhosis and/or HCC. KIR haplotypes do not seem to be associated with immunosuppression status among HIV positive person. Further investigations are in need to fully understand the clinical signifi cance of KIR Haplotype in HBV, HIV disease progression to improve patient's managements in Burkina.